EW
Edwards Lifesciences Corp

4,907
Loading...
Loading...
News
all
press releases
TLRY Gears Up to Report Q1 Earnings: Cannabis Recovery in Focus
Tilray Brands' fiscal first-quarter report is likely to highlight international cannabis gains, European expansion and wellness growth.
Zacks·16h ago
News Placeholder
More News
News Placeholder
AngioDynamics (ANGO) Reports Q1 Loss, Tops Revenue Estimates
AngioDynamics (ANGO) delivered earnings and revenue surprises of +28.57% and +4.75%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7d ago
News Placeholder
Top Stock Reports for Apple, Novartis & Charles Schwab
Apple grows Services to 1B+ paid subscribers, while Novartis lifts guidance and Schwab rides higher rates to asset gains.
Zacks·1mo ago
News Placeholder
ABT vs. EW: Which Structural Heart Device Stock Is Worth Buying Now?
As the structural heart market expands, Abbott and Edwards battle for leadership. Which stock holds stronger growth momentum now?
Zacks·1mo ago
News Placeholder
Nvidia, Citi, AT&T, Lucid, Edwards Sciences: What Sparked Heavy After-Hours Trading In These 5 Stocks?
vidia continues to make waves and struggling electric-vehicle maker Lucid’s reacted to the news of an imminent reverse stock split.
Stocktwits·2mo ago
News Placeholder
Abbott Taps Growing TMVR Market With Tendyne System
ABT wins FDA nod for its Tendyne TMVR system, offering a minimally invasive option for patients with severe mitral valve disease.
Zacks·2mo ago
News Placeholder
Pediatrix Medical's Q2 Earnings Beat on Strong Patient Volumes
MD's Q2 earnings benefit from higher patient volumes and a declining expense level. It now projects 2025 adjusted EBITDA within $245-$255 million, up from the prior view of $220-$240 million.
Zacks·2mo ago
News Placeholder
ENSG's Q2 Earnings Beat on Higher Occupancy Rates, Stock Up 9%
Ensign Group's Q2 earnings improve 20.5% year over year, fueled by stronger occupancy, patient days and rental revenues.
Zacks·2mo ago
News Placeholder
HCA Beats Q2 Earnings on Higher Admissions, Ups '25 EPS View
HCA Healthcare's Q2 earnings rose 24% year over year on stronger patient volumes. EPS for 2025 is expected to be within $25.5-$27, up from the earlier view of $24.05-$25.85.
Zacks·3mo ago
News Placeholder
EW Stock Climbs on Q2 Earnings & Revenue Beat, Margins Down
Edwards Lifesciences posts a second-quarter 2025 earnings and revenue beat, with strong growth in TAVR and TMTT segments despite margin pressure.
Zacks·3mo ago

Latest EW News

View

Advertisement|Remove ads.

Advertisement|Remove ads.